MARKSMAN HEALTHCARE | SCIENTIFIC OUTSOURCING AND RESEARCH CONSULTING

In this progressing and increasingly competitive commercial landscape, attaining optimal market access is becoming extra challenging for pharmaceutical/medical device patrons. In the stir of the global economic crisis, ever increasing costs and abating healthcare budgets, payers have a significant and growing influence on a product's commercial success. The need to demonstrate clinical and economic evidence of a product to providers, healthcare decision-makers and payers is becoming the central component to a product's success.

MarksMan Healthcare Solutions, a non-profit division of path finders charitable trust, is a scientific outsourcing and research consulting, committed in providing the highest level scientific evidence to optimize the value and health impact of medicines and health technologies. We offer customised information solutions for all stages of product’s life-cycle and therapeutic categories. We utilize the expertise of our trained professionals to provide accurate, consistent and concise product, disease and therapeutic area information.

Our experienced and trained analytics team provides HEOR, RWE and PRMA support to large and small life science companies. Besides that, we also provide services pertaining to “Medical Affairs, Clinical Data Management, Drug Safety and Pharmacovigilance”.


 OUR SERVICES

 

  • Meta Research

  • Health Economics and Outcomes Research

  • Real World Evidence

  • Scientific Publications

  • Clinical Research and Regulatory Affairs

  • Pharmacovigilance Writing

  • Bio-statistics

  • Bio-curation

  • Query Management

LATEST FROM BLOG


13Oct 2017

The term real-world evidence (RWE) is commonly used to refer to non-randomized clinical trial (RCT) data generated in a healthcare setting, which sometimes extends to cover patient socio-economic data and environmental data. Irrespective of the definition, RWE is seen to offer significant advantages over randomized controlled trials (RCTs), which despite being recognized as the gold […]

04Oct 2017

There’s a huge load on both pharmaceutical industry and academia in terms of data and information that is circulated through documents such as study protocols, reports, investigator brochures, manuscripts, and several other regulatory and marketing publications. Both writers and reviewers of these documents are overwhelmed with data and information overload, more so while adhering to […]

21Sep 2017

Missing data are a big concern in any research project; however, despite investigators’ best efforts they are often unavoidable. Missing outcomes have two effects: they reduce precision and power, and they may introduce bias. The statistician can’t do much about the loss of precision, except to make best use of the data that are available; […]


International Presentations

  1. 1
    Efficacy and Safety of Oxaliplatin/Capecitabine Based Chemotherapy Plus Bevacizumab as First-line Treatment for Advanced Colorectal Cancer: A Systematic Review and Meta analysis

    ISPOR 22nd Annual International Meeting, May 20-24, 2017, Boston, MA, USA 

  2. 2
    Safety Profile of Daclizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta Analysis

    ISPOR 19th Annual European Congress, 29 October-2 November 2016, Vienna, Austria

  3. 3
    Mepolizumab for the Treatment of Chronic Asthma. A Meta-Analysis of Randomized Placebo-Controlled Trials

    ISPOR 21st Annual International Meeting, May 21-25, 2016, Washington, DC, USA

  4. 4
    Comparison of T-piece Resuscitator with Other Flow – Inflating Bags for Providing Positive Pressure Ventilation During Neonatal Resuscitation: A Systematic Review

    ISPOR 18 Annual European Congress, 7-11 November, 2015, Milan, Italy

  5. 5
    Efficacy And Safety Of Canagliflozin Among Patients With Type 2 Diabetes Mellitus: A Systematic Review And Meta-Analysis

    ISPOR 20th Annual International Meeting, May 16 – 20, 2015, Philadelphia, PA, USA

More